Patent applications published 17 February 2010

Published: 10-Mar-2010
Patient Experience

Patent applications taken from the weekly European Patents Bulletin


  • Compsns of (-)-E-10-OH-NT and methods for the synthesis and use
    Adolor 2152074*

  • Methods and compsns for promoting localisation of pharmaceutically active agents to bone
    Affinergy 2152075*

  • Pulsatile dosing of gossypol for treatment of disease
    Ascenta Therapeutics 2152076*

  • Formulations containing clopidogrel and sulphoalkyl ether cyclodextrin and methods of use
    CyDex Pharmaceuticals 2152078*

  • Heterocyclic compounds and uses thereof
    Avila Therapeutics 2152079*

  • Novel soluble 1,4-benzodiazepine compounds and stable salts thereof
    The Regents of the University of Michigan 2152080*

  • Novel compounds
    High Point Pharmaceuticals 2152081*

  • Tetracyclic inhibitors of fatty acid amide hydrolase
    The Scripps Research Institute 2152082*

  • Method of manufacturing a ruthenium complex
    Niki Pharma 2152084*

  • Erythropoietin complementation or replacement
    Normoxys 2152085*

  • Methods and compsns for administration of oxybutynin
    MicroDose Therapeutx 2152232*

  • High concentration factor VII polypeptide formulations comprising an aromatic preservative and an antioxidant
    Novo Nordisk Health Care 2152233*

  • Lyophilised pharmaceutical compsns and methods of making and using same
    Cephalon; Cephalon France 2152234*

  • Aqueous aerosol preparations containing therapeutically active micro-organisms or parts of micro-organisms and method for producing corresponding aerosols
    Boehringer Ingelheim International 2152235*

  • Pharmaceutical compsn of an anthracycline
    Nerviano Medical Services 2152236*

  • Novel pharmaceutical compsn
    SmithKline Beecham 2152237*

  • Oronasopharyngeally deliverable pharmaceutical compsns of dopamine agonists for the prevention and/or treatment of restless limb disorders
    Schwarz Pharma 2152238*

  • Stable oxalaplatin compsn for parenteral administration
    Intas Pharmaceuticals 2152239*

  • Pharmaceutical compsns and methods for enhancing targeting of therapeutic compounds to the central nervous system
    Healthpartners Research Foundation 2152240*

  • Method of delivering a protein into a cell
    Agency for Science, Technology and Research 2152241*

  • Highly concentrated insulin solutions and compsns
    Novo Nordisk 2152243*

  • Oral delivery of proteins and peptides
    Technion Research & Development Foundation 2152244*

  • Method for drying a protein compsn, a dried protein compsn and a pharmaceutical compsn containing the dried protein
    Novo Nordisk 2152245*

  • Solid compsn comprising a clay such as kaolin
    GlaxoSmithKline Consumer Healthcare 2142246*

  • Anti-insomnia compsns and methods
    Novadel Pharma 2152247*

  • Controlled release tablet formulation containing magnesium aluminometasilicate
    Jagotec 2152248*

  • Oral dosage form providing fast absorption of drug
    Novartis 2152249*

  • Solid dosage forms comprising an enteric coating with accelerated drug release
    Evonik Roehm 2152250*

  • Increased drug loading capacity of polymeric material
    Medtronic 2152251*

  • Selective proteasome inhibitors for treating diabetes
    The Trustees of Columbia University in the City of New York 2152252*

  • Synergistic active preparations comprising 1,2-decanediol and further antimicrobial active compounds
    Symrise 2152253*

  • Reservatrol containing compsn for modulating bone formation
    Uniaeo Brasileira De Educacao E Assistencia 2152254*

  • Ophthalmic formulations of amyloid-contrast agents and methods of use thereof
    Neuroptix 2152255*

  • Telomerase activating compounds and methods of use thereof
    Ben Gurion University of the Negev Research and Development Authority 2152256*

  • Diabetic wound healing
    CytRx 2152257*

  • Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acrinide and uses thereof
    Avalon Pharmaceuticals 2152258*

  • Use of a naphtoic acid derivative in combination with red and/or blue light for treating acne vulgaris
    Galderma Research & Development 2152259*

  • An antibacterial formulation comprising a dialkyl sulphosuccinate and a carbanilide antibacterial agent
    Synoptix 2152260*

  • Treatment of virally induced lesions
    Peplin Research 2152261*

  • New heterocyclic derivatives useful for the treatment of CNS disorders
    UCB Pharma 2152262*

  • Compsns useful for treating gastrooesophageal reflux disease
    Dynogen Pharmaceuticals 2152263*

  • Antimicrobial formulations of a pyridine thiol and a bis-quinolinium salt
    Synoptix Group 2152264*

  • New method for preparing isofagomine and its derivatives
    Amicus Therapeutics 2152265*

  • Compsns and methods for treating disorders associated with salt or fluid retention
    Ironwood Pharmaceuticals 2152266*

  • Treatment of Imatinib resistant leukaemia using 4-aminoquinoline-3-carbonitriles
    Wyeth 2152267*

  • Method of treating diabetes
    CV Therapeutics 2152268*

  • Piperadine/piperazine derivatives
    Janssen Pharmaceutica 2152269*

  • Piperadine/piperazine derivatives
    Janssen Pharmaceutica 2152270*

  • Piperadine/piperazine derivatives
    Janssen Pharmaceutica 2152271*

  • Novel 2,3-diamino-quinazolinone derivatives and their medical use
    NeuroSearch 2152272*

  • Polymerase inhibitors and the use thereof for the treatment of tumours
    Freie Universitaet Berlin; Heinrich-Heine-Universitaet Dusseldorf 2152273*

  • Nasal administration of benzodiazepines
    Questor Pharmaceuticals 2152274*

  • Method of identifying genes involved in memory formation using small interfering RNA (SIRNA)
    Helicon Therapeutics 2152275*

  • Screening assay to identify correctors of protein trafficking defects
    Traffick Therapeutics 2152276*

  • Amido-amine dendrimer compsns
    Genzyme 2152277*

  • Enhancement of the calcium sensing receptor
    Smith & Nephew 2152278*

  • Use of biological surfactant as anti--inflammatory agent and tissue preservation solution
    Seoul National University Industry Foundation 2152279*

  • Branched-chain amino acid compsn for improving skeletal muscle protein metabolism
    Northern Innovations and Formulations 2152280*

  • Compsn for the treatment of ischaemic heart disease, facilitation of blood circulation and angiogenesis, improving skin beauty, improving male sexual function containing genseng berry extract
    Amorepaccfi 2152281*

  • Method and preparation of herbal extract of calotropis gigantea for cancer treatment
    Zacharia, Jacob 2152282*

  • Water soluble opuntia extracts for the inhibition of alpha-1-adrenergic receptors
    Naturamed 2152283*

  • Compsn for maintaining androgen and androgen-like uptake potential by cells
    Northern Innovations and Formulations 2152285*

  • Herbal formulation for treatment of depression and other related disorders and method of preparing the same
    Vita Green Health Products 2152286*

  • Methods for treating and preventing GI syndrome and graft versus host disease
    Sloan Kettering Institute for Cancer Research 2152287*

  • Reconstituted surfactants having improved properties
    Chiesi Farmaceutici 2152288*

  • Novel antimicrobial agents
    Technion Research & Development Foundation 2152289*

  • Method for administering anti-IL-5 antibodies
    SmithKline Beecham 2152290*

  • Use of cyclosporines in the treatment of patients with intraocular lenses
    Allergan 2152291*

  • Angiogenesis inhibitor comprising meteorin as an active ingredient
    SNU R&DB Foundation 2152292*

  • Compsns for protein delivery and methods of use thereof
    The Board of Regents of the University of Nebraska 2152293*

  • Methods of modulating homeostatic pathways and cellular survival
    Dana-Farber Cancer Institute 2152294*

  • Klotho protein and related compounds for the treatment and diagnosis of cancer
    Tel HaShomer Medical Research Infrastructure and Services; Cedars-Sinai Medical Centre 2152295*

  • Injectable ready to use solutions comprising human chorionic gonadotropin
    Dong-a-Pharm 2152296*

  • Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
    Alize Pharma 2152297*

  • Modified nucleotide sequence encoding glucagon-like peptide-1 (GLP-1)
    Boehringer Ingelheim International 2152298*

  • Pharmaceutical and/or cosmetic compsn containing aconitase-activating active ingredients
    Societe d"Extraction des Principes Actifs 2152299*

  • Functional humanisation of complementarity determining regions
    Sinomab Bioscience 2152300*

  • Trypanosoma antigens, vaccine compsns and related methods
    Fraunhofer USA 2152301*

  • Formulation of meningitis vaccines
    Novartis 2152302*

  • Chlamydial antigens as reagents for diagnosis and treatment of chalmydial infection and disease
    Board of Regents, The University of Texas System 2152303*

  • Nanoemulsion therapeutic compsns and methods of using the same
    The Regents of the University of Michigan 2152304*

  • Immediate protection against pathogens via MVA
    Bavarian Nordic 2152305*

  • PRRSV vaccines based on GP5 proteins
    MJ Biologics 2152306*

  • Inhibition of tumour metastasis by anti-neuropilin 2 antibodies
    Genentech 2152307*

  • New indications for anti IL-1-Beta therapy
    Novartis 2152308*

  • Methods and device to neutralise soluble toxic agents in the brain
    Medtronic 2152309*

  • Methods for administering anti-IL-5 antibodies
    SmithKline Beecham 2152310*

  • Set of means for treating a malignant pathology, an autoimmune disease or an infectious disease
    LFB Biotechnologies 2152311*

  • Low-viscous anthracycline formulation
    KTB Tumorforschungs-gesellschaft 2152312*

  • Oral nicotine formulation buffered with amino acid
    McNeil 2152313*
See more

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

Read more
The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape

Trending Articles

  1. AZ enters agreement with Hanmi and Amneal in US Nexium patent litigation AZ says this removes need for a trial and avoids ‘considerable’ costs
  2. Diba Industries announces issuance of US patent for multistage syringe assembly For more than 30 years, Diba Industries, Inc. has delivered precision fluid handling solutions to global OEM leaders in diagnostics, life sciences and medical devices
  3. Phillips-Medisize acquires mini-tablet dispenser patent The US company has acquired exclusive ownership of the patent from a global pharmaceutical company and expects to make the product available by early 2020
  4. Pharma cybersecurity challenges: a holistic prescription The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape
  5. Ilya Pharma awarded engineered lactic acid bacterial strain patent The patent covers the use of engineered lactic acid bacterial strains for all human and animal wounds, not just skin

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape
Regulatory

Pharmaseal reaches milestone in crowdfunding campaign

The company was first founded in 2016
Patient Experience

Ilya Pharma awarded engineered lactic acid bacterial strain patent

The patent covers the use of engineered lactic acid bacterial strains for all human and animal wounds, not just skin
Pharmaceutical

A card in the competition for COVID-19 drug supply

The patent system has come under pressure both politically and, more recently, as pharma companies scale-up their operations to make large amounts of drugs available to treat COVID-19, reports Paul England, Senior Professional Support Lawyer at Taylor Wessing
Ingredients

Sigrid Therapeutics obtains US patent for silica-based biomaterial SiPore15 for the treatment and prevention of obesity

Mesoporous silica particles (MSP) are a type of ingestible synthetic amorphous silica particles that can be produced with a large surface area and a range of pore sizes
Ingredients

VistaGen and Nuformix agree to develop cocrystalline forms of AV-101

The drug for treatment of multiple CNS conditions will be reformed into a novel patentable form to potentially improve delivery and give more intellectual property protection
Digital

Documentation complexity at crisis point?

Do we focus too much on the paperwork, to the detriment of product and patients? Has documentation become so complex it’s become a dangerous distraction and your biggest risk? by Martin Lush
Subscribe now